<DOC>
	<DOCNO>NCT00189488</DOCNO>
	<brief_summary>The main purpose study evaluate effect palifermin versus placebo reduction severe acute graft versus host disease ( GVHD ) severe oral mucositis .</brief_summary>
	<brief_title>Trial Evaluate Palifermin Reduction Acute Graft Versus Host Disease Patients With Hematologic Malignancies Undergoing Allogeneic Marrow/Peripheral Blood Progenitor Cell ( PBPC ) Transplantation</brief_title>
	<detailed_description />
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Graft v Host Disease</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<criteria>Subjects hematologic malignancy ( include myelodysplastic syndrome [ MDS ] ) consider eligible Cyclophosphamide ( Cy ) /Total Body Irradiation ( TBI ) +/ Etoposide ( VP16 ) ; Total Body Irradiation ( TBI ) / Etoposide ( VP16 ) ; Melphalan ( Mel ) / Total Body Irradiation ( TBI ) ; Busulfan ( Bu ) / Cyclophosphamide ( Cy ) ; Busulfan ( Bu ) / Melphalan ( Mel ) ; Fludarabine ( Flu ) / Melphalan ( Mel ) condition therapy allogeneic stem cell support Subjects 6/6 Human Leukocyte Antigen ( HLA ) match family member unrelated donor would provide donor marrow/ peripheral progenitor stem cell . [ For unrelated matched donor , molecular type class I class II mandatory ] Karnofsky Performance Status &gt; = 70 % 18 year age old time inform consent Before studyspecific procedure , appropriate write informed consent must obtain Cancer NonHodgkin 's lymphoma , Hodgkin 's disease , acute myelogenous leukemia , acute lymphoblastic leukemia , chronic myelogenous leukemia , chronic lymphocytic leukemia , myelodysplastic syndrome multiple myeloma ( except : adequately treat basal cell carcinoma skin ) Prior autologous allogeneic bone marrow peripheral blood stem cell transplantation Previous use palifermin Current active infection ( include human immunodeficiency virus ( HIV ) hepatitis ) oral mucositis Congestive heart failure define New York Heart Association class III IV Graft Tcell depletion Graftversushost disease ( GVHD ) prophylaxis Inadequate renal function ( serum creatinine &gt; 1.5x upper limit normal per institutional guideline clearance &lt; 40 ml/min adjust age ) Inadequate liver function ( total bilirubin &gt; 1.5x upper limit normal , aspartate aminotransferase ( AST ) &gt; 3x upper limit normal and/or alanine aminotransferase ( ALT ) &gt; 3x upper limit normal per institutional guideline ) Inadequate pulmonary function measure correct DLCO ( diffuse capacity lung carbon monoxide lung function test ) &lt; 50 % predict Subject currently enrol yet complete least 30 day since end investigational device drug trial ( ) , subject receive investigational agent ( ) Subject childbearing potential evidently pregnant ( e.g . positive human chorionic gonadotropin HCG test ) breast feed Part A study Subject partner subject use refuse use adequate contraceptive precaution Part A study Subject know sensitivity product administer dose include Escherichia coliderived product Subject previously randomize study Subject available followup assessment Subject kind disorder compromise ability subject give write informed consent and/or comply study procedure</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2014</verification_date>
	<keyword>Hematological Malignancies</keyword>
	<keyword>Graft-versus-host-disease</keyword>
	<keyword>Oral Mucositis</keyword>
	<keyword>Allogeneic Transplantation</keyword>
</DOC>